Leader, Myeloproliferative Disorders Program; Professor, Member and Attending Physician, Memorial Sloan Kettering Cancer Center
Hematology
Dr. Michael D. Mauro, DO
|
|
Give Review
Michael Mauro is an expert in the field of Hematology. He studied medicine at Geisel School of Medicine at Dartmouth. Geisel School of Medicine at Dartmouth has a rank of 37 in research and a 29 in primary care He has 1 awards "CMS Meaningful Use Stage 1 Certification". Michael Mauro is a published MD. He has 43 papers published. The most current publication "Clinical features of pulmonary arterial hypertension in patients receiving dasatinib."
Publications
- Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
- Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
- Prognostic significance of early molecular response in Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
- Integrating Current Treatment Options for TKI-Resistant Chronic Myeloid Leukemia: General Discussion.
- Extending the reach of nilotinib in Chronic myeloid leukemia.
- The challenge of the 'C' in CML.
- Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib.
- Sequential therapy in Chronic myelogenous leukemia: general discussion.
- Striving to achieve safe, permanent treatment discontinuation in Chronic myeloid leukemia.
- Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.
- Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.
- Clinical roundtable monograph: Emerging treatment options for TKI-resistant Chronic myelogenous leukemia.
- Will Imatinib Compromise Reproductive Capacity?
- Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.
- Intolerance to tyrosine kinase inhibitors in Chronic myeloid leukemia: Definitions and clinical implications.
- Epidemiologic study on survival of Chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.
- Drug plasma monitoring in CML and GIST: A case-based Discussion.
- Review: Imatinib plasma trough levels in the management of CML: Ready for prime time?
- Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with Chronic myeloid leukemia on imatinib.
- Response dynamics in Chronic-phase Chronic myeloid leukemia.
- Tailoring tyrosine kinase inhibitor therapy in Chronic myeloid leukemia.
- Appropriate sequencing of tyrosine kinase inhibitors in Chronic myelogenous leukemia: when to change? A perspective in 2009.
- An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in Chronic myeloid leukemia patients undergoing kinase inhibitor therapy.
- A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with Chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
- Mutational analysis and overcoming imatinib resistance in Chronic myeloid leukemia with novel tyrosine kinase inhibitors.
- BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
- Stem cell transplantation in patients with Chronic myelogenous leukemia: when should it be used?
- Defining and managing imatinib resistance.
- Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
- Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of Chronic phase CML patients treated with imatinib mesylate.
- Images in clinical medicine. Hyperleukocytosis in acute myeloid leukemia.
- STI571 as a targeted therapy for CML.
- The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.
- Hematopathologic and cytogenetic findings in imatinib mesylate-treated Chronic myelogenous leukemia patients: 14 months' experience.
- STI571: a paradigm of new agents for cancer therapeutics.
- Recent advancements in the treatment of Chronic myelogenous leukemia.
- Overcoming Resistance in Chronic Myelogenous Leukemia.
- Management of drug toxicities in Chronic myeloid leukaemia.
- Chronic myeloid leukemia in 2006: a perspective.
- Divergent clinical outcome in two CML patients who Discontinued imatinib therapy after achieving a molecular remission.
- Baseline disease risk and response to therapy in Chronic myeloid leukemia: necessary predictive tools then and now.
- Transplantation for Chronic myelogenous leukemia: yes, no, maybe so. . . An Oregon perspective.
Schools
Kirksville College of Osteopathic Medicine
Grandview Hosp amp Med Ctr
Grandview Hosp Med Ctr
Johns Hospkins Hosp
Daeman College
Procedures Preformed
- Dressing and-or Debridement of Wound, Infection, or Burn (incl. Negative Pressure Wound Therapy)
- Dural Repair or Other Spinal Spinal Cord Repair
- Foot and Ankle Fracture Treatment, Open
- Hand and Wrist Fracture Treatment, Closed
- View All
Conditions Treated
- Achilles Tendinitis
- Adhesive Capsulitis
- Ankle Fracture
- Ankle Sprain and Achilles Tendon Sprain or Rupture
- View All
Doctors Specialties
- Orthopedic Spine Surgery
- Orthopedic Surgery
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
New York Presbyterian Hospital -
New York Presbyterian Hospital - Cornell Campus -
Geisel School of Medicine at Dartmouth
Hospital
-
Memorial Sloan-Kettering Cancer Center
Drug Facts
| NPI NUMBER | 1285811695 | |
| NPPES Provider LastName | MAURO | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 240736345 | |
| NPPES Provider State | VA | |
| Specialty Description | Orthopedic Surgery | |
| Total Claim Count | 39.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285811695 |
| Last Name Of The Provider | MAURO |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
Dr. Stephen A. Grubb, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert M. Rotche, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Edward L. McDowell, PA-C |